2 μg(R: reducing conditions)
Product Details
Product Details
Product Specification
Species | Human |
Synonyms | Platelet-activating factor acetylhydrolase, PAF acetylhydrolase, 1-alkyl-2-acetylglycerophosphocholine esterase, 2-acetyl-1-alkylglycerophosphocholine esterase, Group-VIIA phospholipase A2 (gVIIA-PLA2), LDL-associated phospholipase A2 (LDL-PLA(2)), PAF 2-acylhydrolase, PAFAH |
Accession | Q13093 |
Amino Acid Sequence | Protein sequence (Q13093, Phe22-Asn441, with C-His tag) FDWQYINPVAHMKSSAWVNKIQVLMAAASFGQTKIPRGNGPYSVGCTDLMFDHTNKGTFLRLYYPSQDNDRLDTLWIPNKEYFWGLSKFLGTHWLMGNILRLLFGSMTTPANWNSPLRPGEKYPLVVFSHGLGAFRTLYSAIGIDLASHGFIVAAVEHRDRSASATYYFKDQSAAEIGDKSWLYLRTLKQEEETHIRNEQVRQRAKECSQALSLILDIDHGKPVKNALDLKFDMEQLKDSIDREKIAVIGHSFGGATVIQTLSEDQRFRCGIALDAWMFPLGDEVYSRIPQPLFFINSEYFQYPANIIKMKKCYSPDKERKMITIRGSVHQNFADFTFATGKIIGHMLKLKGDIDSNVAIDLSNKASLAFLQKHLGLHKDFDQWDCLIEGDDENLIPGTNINTTNQHIMLQNSSGIEKYN |
Expression System | HEK293 |
Molecular Weight | Predicted MW: 49.5 kDa Observed MW: 55-70 kDa |
Purity | >90% by SDS-PAGE |
Endotoxin | <0.1EU/μg |
Tag | with C-His tag |
Physical Appearance | Lyophilized Powder |
Storage Buffer | Lyophilized from a 0.2 μm filtered solution of 0.2M PBS, pH7.4. |
Reconstitution | Reconstitute no more than 1 mg/mL according to the size in deionized water after rapid centrifugation. |
Stability & Storage | 12 months from date of receipt, -20 to -70 °C as supplied. |
Background
Lipoprotein-associated phospholipase A2 (Lp-PLA2) also known as platelet-activating factor acetylhydrolase (PAF-AH) is a phospholipase A2 enzyme. It is one of several PAF acetylhydrolases that catalyzes the degradation of PAF to inactive products by hydrolysis of the acetyl group at the sn-2 position, producing the biologically inactive products LYSO-PAF and acetate. It is an enzyme produced by inflammatory cells and hydrolyzes oxidized phospholipids in LDL. In the blood Lp-PLA2 travels mainly with low-density lipoprotein (LDL). Less than 20% is associated with high-density lipoprotein HDL. HDL-associated Lp-PLA2 may substantially contribute to the HDL antiatherogenic activities. In human atherosclerotic lesions, 2 main sources of Lp-PLA2 can be identified, including that which is brought into the intima bound to LDL (from the circulation), and that which is synthesized de novo by plaque inflammatory cells (macrophages, T cells, mast cells). It is used as a marker for cardiac disease. Lp-PLA2 levels are positively correlated with increased risk of developing coronary heart disease and stroke.
Picture
Picture
SDS-PAGE
